Diligence memo · auto-generated · as of July 2, 2026
Nanoviricides, Inc.
Nanoviricides, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Nanoviricides, Inc. operates in Pharmaceuticals, based in SHELTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nanoviricides, Inc. has raised $15M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.0M on 2013-02-01.
Most recent recorded round closed around 2025-11-12.
Valuation (modeled)modeled
Provath models Nanoviricides, Inc. at approximately $17M (range $6.9M–$26M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.04× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era. Within the normal band (104% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 77 months.
Last raise 8 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 2.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 60% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 25% of those peers.
Closest niche peers: Incannex Healthcare Inc., Retension Pharmaceuticals, Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.